Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 1
2000 5
2001 2
2002 6
2003 7
2004 12
2005 9
2006 16
2007 20
2008 23
2009 20
2010 27
2011 33
2012 41
2013 27
2014 15
2015 19
2016 15
2017 12
2018 8
2019 10
2020 13
2021 9
2022 8
2023 6
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

328 results

Results by year

Filters applied: . Clear all
Page 1
Drospirenone/ethinyl estradiol.
Rapkin AJ, Sorger SN, Winer SA. Rapkin AJ, et al. Drugs Today (Barc). 2008 Feb;44(2):133-45. doi: 10.1358/dot.2008.44.2.1191057. Drugs Today (Barc). 2008. PMID: 18389090 Review.
Drospirenone 3 mg/ethinyl estradiol 20 microg (24/4) is a new unique oral contraceptive formulation that combines in a novel dosing regimen the lowest dosage of ethinyl estradiol commonly used today with drospirenone, an innovative progestin. ...The prolongation of
Drospirenone 3 mg/ethinyl estradiol 20 microg (24/4) is a new unique oral contraceptive formulation that combines in a novel dosing r
Combined oral contraceptives: venous thrombosis.
de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. de Bastos M, et al. Cochrane Database Syst Rev. 2014 Mar 3;2014(3):CD010813. doi: 10.1002/14651858.CD010813.pub2. Cochrane Database Syst Rev. 2014. PMID: 24590565 Free PMC article. Review.
The relative risk of venous thrombosis for combined oral contraceptives with 30-35 mug ethinylestradiol and gestodene, desogestrel, cyproterone acetate, or drospirenone were similar and about 50-80% higher than for combined oral contraceptives with levonorgestrel. ...Risk …
The relative risk of venous thrombosis for combined oral contraceptives with 30-35 mug ethinylestradiol and gestodene, desogestrel, cyproter …
Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen.
Regidor PA, Mueller A, Mayr M. Regidor PA, et al. Womens Health (Lond). 2023 Jan-Dec;19:17455057221147388. doi: 10.1177/17455057221147388. Womens Health (Lond). 2023. PMID: 36744531 Free PMC article. Review.
Ethinylestradiol, an inhibitor of CYP metabolic enzymes, changes the pharmacokinetics of drospirenone, leading to a higher drospirenone exposure with ethinylestradiol/drospirenone compared to the drospirenone-only preparation. ...There is no influence …
Ethinylestradiol, an inhibitor of CYP metabolic enzymes, changes the pharmacokinetics of drospirenone, leading to a higher drospir
Treatment of lean PCOS teenagers: a follow-up comparison between Myo-Inositol and oral contraceptives.
Pkhaladze L, Russo M, Unfer V, Nordio M, Basciani S, Khomasuridze A. Pkhaladze L, et al. Eur Rev Med Pharmacol Sci. 2021 Dec;25(23):7476-7485. doi: 10.26355/eurrev_202112_27447. Eur Rev Med Pharmacol Sci. 2021. PMID: 34919250 Free article. Clinical Trial.
They were treated for 3 months either with oral contraceptive pills (OCP) drospirenone/ethinylestradiol (group A), myo-Inositol (myo-Ins) (group B), or OCP plus myo-Ins (group C). ...
They were treated for 3 months either with oral contraceptive pills (OCP) drospirenone/ethinylestradiol (group A), myo-Inositol (myo- …
The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium.
Rapkin RB, Creinin MD. Rapkin RB, et al. Expert Opin Pharmacother. 2011 Oct;12(15):2403-10. doi: 10.1517/14656566.2011.610791. Epub 2011 Aug 31. Expert Opin Pharmacother. 2011. PMID: 21877996 Review.
A new oral contraceptive containing drospirenone and ethinyl estradiol plus levomefolate calcium was formulated to decrease the risk of neural tube defects in pregnancies conceived while taking or shortly after discontinuing this pill. ...Additionally, we review studies ev …
A new oral contraceptive containing drospirenone and ethinyl estradiol plus levomefolate calcium was formulated to decrease the risk …
Comparison of estrogenic components used for hormonal contraception.
Stanczyk FZ, Winer SA, Foidart JM, Archer DF. Stanczyk FZ, et al. Contraception. 2024 Feb;130:110310. doi: 10.1016/j.contraception.2023.110310. Epub 2023 Oct 18. Contraception. 2024. PMID: 37863464 Review.
Recently, a COC incorporating a novel weak natural estrogen, estetrol (E(4)), combined with drospirenone, has become available. We present a comparative analysis of the three prevailing estrogens used in COCs, focusing on their structure-function relationships, receptor-bi …
Recently, a COC incorporating a novel weak natural estrogen, estetrol (E(4)), combined with drospirenone, has become available. We pr …
Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results.
Creinin MD, Westhoff CL, Bouchard C, Chen MJ, Jensen JT, Kaunitz AM, Achilles SL, Foidart JM, Archer DF. Creinin MD, et al. Contraception. 2021 Sep;104(3):222-228. doi: 10.1016/j.contraception.2021.05.002. Epub 2021 May 15. Contraception. 2021. PMID: 34000251 Free article. Clinical Trial.
OBJECTIVE: To assess efficacy, cycle control, and safety of an oral contraceptive containing estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg. STUDY DESIGN: Women aged 16 to 50 years with a body mass index 35 kg/m(2) enrolled in this multicenter, open-label, 13-cycle, phas …
OBJECTIVE: To assess efficacy, cycle control, and safety of an oral contraceptive containing estetrol (E4) 15 mg and drospirenone (DR …
A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.
Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME. Dragoman MV, et al. Int J Gynaecol Obstet. 2018 Jun;141(3):287-294. doi: 10.1002/ijgo.12455. Epub 2018 Feb 22. Int J Gynaecol Obstet. 2018. PMID: 29388678 Free PMC article. Review.
The use of COCs containing cyproterone acetate, desogestrel, drospirenone, or gestodene was associated with a significantly increased risk of VTE compared with the use of levonorgestrel-containing COCs (pooled risk ratios 1.5-2.0). ...
The use of COCs containing cyproterone acetate, desogestrel, drospirenone, or gestodene was associated with a significantly increased …
Effectiveness and safety assessment of drospirenone/ethinyl estradiol tablet in treatment of PCOS patients: a single center, prospective, observational study.
Li L, Zhang R, Zeng J, Ke H, Peng X, Huang L, Zhang H, Chen Z, Li TT, Tan Q, Yang Y, Li X, Li X. Li L, et al. BMC Womens Health. 2020 Feb 27;20(1):39. doi: 10.1186/s12905-020-00905-x. BMC Womens Health. 2020. PMID: 32106860 Free PMC article.
BACKGROUND: To investigate the effectiveness and safety of 3 mg drospirenone and 20 mug ethinyl estradiol tablet (3 mg DRSP/20 mug EE) in the treatment of polycystic ovary syndrome (PCOS). ...
BACKGROUND: To investigate the effectiveness and safety of 3 mg drospirenone and 20 mug ethinyl estradiol tablet (3 mg DRSP/20 mug EE …
Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive.
Han L, Jensen JT. Han L, et al. Expert Opin Pharmacother. 2014 Oct;15(14):2071-9. doi: 10.1517/14656566.2014.949237. Epub 2014 Sep 4. Expert Opin Pharmacother. 2014. PMID: 25186109 Review.
Flexible extended dosing of a contraceptive containing drospirenone (DRSP) and ethinyl estradiol (EE) was designed to improve bleeding profiles during extended cycles through active management of bleeding symptoms. ...We will focus on the findings of the two most important …
Flexible extended dosing of a contraceptive containing drospirenone (DRSP) and ethinyl estradiol (EE) was designed to improve bleedin …
328 results